Literature DB >> 2767607

Blood distribution of tenoxicam in humans: a particular HSA drug interaction.

F Bree1, P Nguyen, S Urien, P Riant, E Albengres, H Fenner, J P Tillement.   

Abstract

Blood binding of tenoxicam was studied in vitro by equilibrium dialysis. Isolated human plasma proteins and blood cells were checked, and the distribution of the bound form was then calculated. The results showed that tenoxicam is mainly bound to HSA and that binding percentages are not different when measured in plasma (98.4%) and in an HSA solution at physiological concentration (704 microM, 98.15%). In these conditions, within the range of 1-150 microM, the tenoxicam binding percentage remained constant, evidence of a nonsaturable process. When a lower HSA concentration (10 microM) was used, the binding parameters of the tenoxicam interaction were calculated by using the same equilibrium dialysis data, by 3 methods of analysis- a stoichiometric method and site-oriented methods, fixing or not the number of HSA binding sites (n) as integer values. The best fit was observed with the first method, suggesting that two main interactions occurred. The site-oriented method gave lesser fits, the better being observed when n was not fixed. Its value, 1.77, suggest the possibility of two binding sites, one of them not preformed. The effects of known markers of site I, warfarin and apazone, of site II, diazepam and ibuprofen and of palmitic acid showed that tenoxicam is bound simultaneously to both sites I and II. The binding capacity of site I for tenoxicam is enhanced by diazepam: as this compound alone is bound to site II, this result suggests that the two HSA binding sites are not independent.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2767607     DOI: 10.1111/j.1472-8206.1989.tb00456.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  6 in total

1.  A re-evaluation of the HSA-piroxicam interaction.

Authors:  F Brée; S Urien; P Nguyen; P Riant; E Albengres; J P Tillement
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

2.  Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery.

Authors:  P Jolliet; N Simon; F Brée; S Urien; A Pagliara; P A Carrupt; B Testa; J P Tillement
Journal:  Pharm Res       Date:  1997-05       Impact factor: 4.200

Review 3.  Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic diseases.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

4.  Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers.

Authors:  P J Anderson; J A Critchley; B Tomlinson; G Resplandy
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

5.  Nimesulide binding to components within blood.

Authors:  F Bree; P Nguyen; S Urien; E Albengres; A Macciocchi; J P Tillement
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of tenoxicam.

Authors:  O G Nilsen
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.